ClearPoint Neuro, Inc. — filing identity and reporting period
Important identification: The supplied filing is MRI Interventions, Inc.’s Form 10-K, not a filing under the name ClearPoint Neuro, Inc. It covers the fiscal year ended December 31, 2017; the source does not provide standalone fourth-quarter financial results. The company’s commercial product was the ClearPoint system, an MRI-guided platform for minimally invasive brain procedures. ClearTrace, its cardiac product candidate, remained suspended in development.
Financial performance and liquidity
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Total revenue | $7.38 million | $5.75 million | +28% |
| Product revenue | $7.02 million | $5.60 million | +25% |
| Gross profit / margin | $4.48 million / 61% | $3.11 million / 54% | Margin +7 percentage points |
| Operating loss | $6.34 million | $7.49 million | Loss narrowed |
| Net loss | $7.17 million | $8.07 million | Loss narrowed 11% |
| Net cash used in operations | $5.99 million | $5.82 million | Cash use increased modestly |
| Cash and equivalents at year-end | $9.29 million | $3.32 million | Up $5.97 million |
Functional neurology disposable revenue rose 34% to $5.3 million, supported by 629 ClearPoint cases, up 25% from 504. Capital equipment, rental and service revenue increased 50% to $1.5 million. Biologics and drug-delivery revenue declined to $563,000 from $771,000, partly reflecting a large Voyager purchase in late 2016.
Year-end total assets were $13.90 million, current assets $12.75 million and current liabilities $4.40 million, implying working capital of approximately $8.35 million. Total liabilities were $8.07 million. The filing reports $6.975 million of scheduled debt principal: $2.0 million due in 2018, $1.975 million in 2019 and $3.0 million in 2020. Debt is secured by company assets. The Brainlab note bears 5.5% interest and matures in December 2018; the 2014 notes bear 12% and mature in 2019; the 2010 notes bear 3.5% and mature in 2020. Balance-sheet debt carrying values are reduced by unamortized discounts and issuance costs.
Financing provided $11.99 million of net cash in 2017, principally from a May private placement. The placement issued 6.625 million shares and warrants for an equal number of shares at $2.20 per share, before placement-agent warrants. Common shares outstanding increased from 3.62 million at year-end 2016 to 10.69 million at year-end 2017. Accumulated deficit was approximately $101 million.
Material changes versus 2016
- Revenue growth and a higher gross margin reflected more ClearPoint procedure utilization, improved product mix, and higher-margin rental and service revenue.
- Operating expenses were broadly stable: R&D rose 7%, sales and marketing rose 5%, while general and administrative expense fell 3%.
- Net loss improved, but comparison was affected by non-operating items. The 2016 period included a $1.07 million derivative fair-value gain and an $812,000 debt-restructuring loss; 2017 included only a $25,000 derivative gain and no debt-restructuring loss. Interest expense declined to $873,000 from $1.05 million.
- Cash increased following the 2017 equity financing, although operating cash use remained approximately $6.0 million.
Outlook, commentary and key risks
Management anticipated higher ClearPoint revenue from increased utilization at existing sites and new installations, with operating expenses rising to support growth. It expected lower operating losses and cash use if plans were achieved, but cautioned that cash would continue to be consumed for at least the next 12 months. Management believed $9.3 million of year-end cash was sufficient for at least 12 months; the filing also warns that failure to obtain further financing could create substantial doubt about the company’s ability to continue as a going concern.
- Commercial and reimbursement risk: ClearPoint adoption depends on physician and hospital acceptance, MRI-suite availability, clinical evidence, budgets, and adequate procedure reimbursement. Products are not separately reimbursed to hospitals.
- Concentration and execution: The company identified significant reliance on a small number of hospital customers, limited manufacturing capacity, and single-source suppliers. Separately, the financial-statement note says no customer exceeded 10% of product revenue in 2017; verify how this reconciles with the broader concentration disclosure.
- Development and regulatory risk: ClearTrace development had been suspended since 2015, with no regulatory submission. The Siemens exclusivity provisions ended after a June 2016 product-release milestone was missed. New ClearPoint indications may require additional FDA clearance or clinical evidence.
- Debt, dilution and refinancing: The 2017 financing materially increased share count and added substantial warrants. The $2.0 million Brainlab note was due in 2018, followed by further principal maturities in 2019 and 2020.
- Other developments: The company entered a Mayo Clinic collaboration for MRI-guided stroke therapies and an Acoustic MedSystems collaboration focused initially on MRI-guided ultrasound ablation for pancreatic cancer. The CEO transition took effect in November 2017. The 2017 tax provision included provisional estimates following the Tax Cuts and Jobs Act; estimates could change with further guidance.
The auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to management’s internal-control assessment.
Important facts for investors to verify
- Confirm the issuer and security being analyzed: this document is for MRI Interventions, Inc., and does not identify ClearPoint Neuro, Inc. as the registrant.
- Review the complete audited statements and notes for debt covenants, collateral priority, interest and principal payment terms, and the ability to refinance the 2018–2020 maturities.
- Assess cash runway against actual operating cash burn, the timing of further financing needs, and management’s 12-month liquidity assertion.
- Verify the fully diluted share count, including outstanding warrants and options, warrant exercise prices and terms, and potential future dilution.
- Track procedure growth, new system placements, recurring disposable sales, gross margin, and customer concentration; do not infer fourth-quarter performance from annual totals.
- Check subsequent filings for ClearTrace plans, partnership milestones, FDA activity, CEO-transition developments, lease arrangements, and any revisions to provisional tax estimates.